Mohammad Mahmoudi Gomari
Overview
Explore the profile of Mohammad Mahmoudi Gomari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomari M, Ghantabpour T, Pourgholam N, Rostami N, Hatfield S, Namazifar F, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 39901621
Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging...
2.
Gomari M, Arab S, Balalaie S, Ramezanpour S, Hosseini A, Dokholyan N, et al.
Proteins
. 2023 Aug;
92(1):76-95.
PMID: 37646459
Cell invasion is an important process in cancer progression and recurrence. Invasion and implantation of cancer cells from their original place to other tissues, by disabling vital organs, challenges the...
3.
Rostami N, Faridghiasi F, Ghebleh A, Noei H, Samadzadeh M, Gomari M, et al.
Polymers (Basel)
. 2023 Jul;
15(14).
PMID: 37514522
Curcumin (CUR) has potent anticancer activities, and its bioformulations, including biodegradable polymers, are increasingly able to improve CUR's solubility, stability, and delivery to cancer cells. In this study, copolymers comprising...
4.
Rostami N, Gomari M, Abdouss M, Moeinzadeh A, Choupani E, Davarnejad R, et al.
ACS Appl Bio Mater
. 2023 Apr;
6(5):1806-1815.
PMID: 37093754
An effective treatment for hormone-dependent breast cancer is chemotherapy using cytotoxic agents such as letrozole (LTZ). However, most anticancer drugs, including LTZ, are classified as class IV biopharmaceuticals, which are...
5.
Choupani E, Gomari M, Zanganeh S, Nasseri S, Haji-Allahverdipoor K, Rostami N, et al.
Pharmacol Rev
. 2023 Feb;
75(2):309-327.
PMID: 36781219
Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to 20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme aggressiveness, (ii) absence...
6.
Mondeali M, Etemadi A, Barkhordari K, Kesheh M, Shavandi S, Bahavar A, et al.
J Cell Biochem
. 2023 Jan;
124(2):308-319.
PMID: 36609701
The attachment of SARA-CoV-2 happens between ACE2 and the receptor binding domain (RBD) on the spike protein. Mutations in this domain can affect the binding affinity of the spike protein...
7.
Gomari M, Abkhiz S, Pour T, Lotfi E, Rostami N, Nafe Monfared F, et al.
Mol Med
. 2022 Dec;
28(1):146.
PMID: 36476230
The low efficiency of treatment strategies is one of the main obstacles to developing cancer inhibitors. Up to now, various classes of therapeutics have been developed to inhibit cancer progression....
8.
Gomari M, Tarighi P, Choupani E, Abkhiz S, Mohamadzadeh M, Rostami N, et al.
Int J Biol Macromol
. 2022 Nov;
226:1116-1140.
PMID: 36435470
One of the main obstacles in prevention and treatment of COVID-19 is the rapid evolution of the SARS-CoV-2 Spike protein. Given that Spike is the main target of common treatments...
9.
Gomari M, Rostami N, Faradonbeh D, Asemaneh H, Esmailnia G, Arab S, et al.
Proteins
. 2022 May;
90(11):1908-1925.
PMID: 35569112
The binding of therapeutics to human serum albumin (HSA), which is an abundant protein in plasma poses a major challenge in drug discovery. Although HSA has several binding pockets, the...
10.
Nateghi S, Gomari M, Roudsari Y, Foroughi A, Mansouri F, Shiva A, et al.
Prim Care Diabetes
. 2022 Mar;
16(3):361-364.
PMID: 35283068
Background: Blood sugar (BS) has been proposed as a prognostic factor for COVID-19. In this historical cohort study we evaluated the association between admission time BS and COVID-19 outcome. Methods:...